CD125 / IL5RA, C-His, recombinant protein

Description of CD125 / IL5RA, C-His, recombinant protein

CD125 / IL5RA: A Crucial Drug Target for Allergic Inflammation

Introduction

CD125, also known as interleukin-5 receptor alpha (IL5RA), is a transmembrane protein that plays a crucial role in the development and maintenance of allergic inflammation. It is a member of the cytokine receptor family and is primarily expressed on the surface of eosinophils, basophils, and mast cells, which are key players in the allergic response. CD125 is a promising drug target for the treatment of various allergic diseases, including asthma, allergic rhinitis, and atopic dermatitis.

Structure of CD125 / IL5RA

CD125 is a type I transmembrane protein with a molecular weight of approximately 70 kDa. It consists of a large extracellular domain, a transmembrane domain, and a short cytoplasmic tail. The extracellular domain of CD125 contains two fibronectin type III domains, which are important for ligand binding. The transmembrane domain anchors the protein to the cell membrane, while the cytoplasmic tail is responsible for signal transduction upon ligand binding.

Activity of CD125 / IL5RA

CD125 is the specific receptor for interleukin-5 (IL-5), a cytokine that plays a critical role in the regulation of eosinophil development, survival, and activation. Upon binding to IL-5, CD125 undergoes a conformational change, leading to the recruitment and activation of signaling molecules, such as Janus kinases (JAKs) and signal transducer and activator of transcription (STAT) proteins. This results in the activation of downstream signaling pathways, leading to the production of pro-inflammatory cytokines and chemokines, and the recruitment and activation of immune cells, particularly eosinophils.

Application of CD125 / IL5RA

CD125 has been identified as a potential drug target for the treatment of various allergic diseases. One of the most promising applications of CD125 is in the treatment of asthma. Asthma is a chronic respiratory disease characterized by airway inflammation, mucus production, and airway hyperresponsiveness. Eosinophils play a crucial role in the pathogenesis of asthma, and IL-5 is a key cytokine involved in the recruitment and activation of these cells. Therefore, targeting CD125 with specific inhibitors can potentially reduce eosinophilic inflammation and improve asthma symptoms.

Another potential application of CD125 is in the treatment of allergic rhinitis, a common condition characterized by inflammation of the nasal passages. IL-5 and eosinophils have been implicated in the pathogenesis of allergic rhinitis, and targeting CD125 can potentially reduce nasal inflammation and improve symptoms.

In addition, CD125 has also been identified as a potential target for the treatment of atopic dermatitis, a chronic inflammatory skin disease. Eosinophils and IL-5 have been shown to play a role in the pathogenesis of atopic dermatitis, and targeting CD125 can potentially reduce skin inflammation and improve symptoms.

Recombinant CD125 / IL5RA Protein

Recombinant CD125 protein, also known as C-His-CD125, is a form of CD125 that has been produced using recombinant DNA technology. It is a highly purified and biologically active protein, which can be used for various research and therapeutic applications. Recombinant CD125 protein has been used in preclinical studies to validate CD125 as a drug target and to develop potential inhibitors for the treatment of allergic diseases.

Conclusion

In conclusion, CD125 / IL5RA is a crucial drug target for the treatment of various allergic diseases. Its structure, activity, and role in the pathogenesis of allergic inflammation make it an attractive target for drug development.